Sugi Predict

Sugi Predict / Compounds / SCHEMBL3092733

SCHEMBL3092733

SCHEMBL3092733

NC(=O)[CH]c1cccnc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.58
▸ RAB9A P51151 3/20 0.58
▸ MAPK1 P28482 2/20 0.58
▸ KDM4E B2RXH2 2/20 0.58
▸ NPC1 O15118 1/20 0.58
▸ JUN P05412 1/20 0.58
▸ NFKB1 P19838 1/20 0.58
▸ GPR55 Q9Y2T6 1/20 0.58
▸ F7 P08709 1/20 0.53
▸ F3 P13726 1/20 0.53
▸ SARM1 Q6SZW1 1/20 0.53
▸ SIRT2 Q8IXJ6 1/20 0.53
▸ SIRT6 Q8N6T7 1/20 0.53
▸ SIRT1 Q96EB6 1/20 0.53
▸ SIRT3 Q9NTG7 1/20 0.53
▸ SIRT5 Q9NXA8 1/20 0.53
▸ SIRT4 Q9Y6E7 1/20 0.53
▸ ALDH1A1 P00352 3/20 0.50
▸ CYP11B2 P19099 2/20 0.50
▸ CYP11B1 P15538 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL83322 0.82 RAB9A (0.73) MAPTRAB9AMAPK1KDM4ENPC1
SCHEMBL83267 0.82 RAB9A (0.73) MAPTRAB9AMAPK1KDM4ENPC1
Nicotinaldehyde SCHEMBL28290769 0.82 MAPT (0.56) MAPTRAB9AMAPK1KDM4ENPC1
Acrylamide SCHEMBL27549876 0.81 MAPT (0.51) MAPTRAB9AMAPK1KDM4ENPC1
SCHEMBL5654405 0.81 MKNK1 (0.56) ALDH1A1CYP11B2CYP11B1CYP19A1CYP1A2
SCHEMBL15758916 0.79 MAPT (0.53) MAPTRAB9AMAPK1KDM4ENPC1
SCHEMBL15758914 0.79 MAPT (0.53) MAPTRAB9AMAPK1KDM4ENPC1
SCHEMBL82827 0.78 RAB9A (0.62) MAPTRAB9AMAPK1KDM4ENPC1
SCHEMBL27515328 0.77 SMN1; SMN2 (0.56) MAPTRAB9AMAPK1KDM4ENPC1
SCHEMBL3465670 0.77 MAPT (0.51) MAPTRAB9AMAPK1KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109563085-B Piperidine CXCR7 receptor modulators 爱杜西亚药品有限公司 2022-08-09 — — CN claimed
EP-3490986-B1 PIPERIDINE CXCR7 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2021-11-24 — — EP claimed
US-10752620-B2 Piperdine CXCR7 receptor modulators IDORSIA PHARMACEUTICALS LTD. (CH) 2020-08-25 — — US claimed
US-20190169180-A1 PIPERDINE CXCR7 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD. (CH) 2019-06-06 — — US claimed
EP-3490986-A1 PIPERIDINE CXCR7 RECEPTOR MODULATORS Idorsia Pharmaceuticals Ltd (CH) 2019-06-05 — — EP claimed
CN-109563085-A piperidine CXCR7 receptor modulators 爱杜西亚药品有限公司 2019-04-02 — — CN claimed
WO-2018019929-A1 PIPERIDINE CXCR7 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2018-02-01 — — WO claimed
EP-2763990-B1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2017-02-22 — — EP claimed
EP-2038264-B1 TETRAZOLE-SUBSTITUTED ARYLAMIDES HOFFMANN LA ROCHE (CH) 2016-10-26 — — EP claimed
US-8658646-B2 Pyrrolopyrazine kinase inhibitors HOFFMANN-LAROCHE INC. (US) 2014-02-25 — — US claimed
US-7569568-B2 Cytokine inhibitors BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2009-08-04 — — US claimed
CN-100471856-C Bicyclic compounds and compostions as PDF inhibitors IRM LLC (BM) 2009-03-25 — — CN claimed
US-20080200504-A1 non-peptide NK-3 receptor ligands; anxiety, depression, schizophrenia, obesity; 2-Phenyl-quinoline-4-carboxylic acid (1-pyridin-4-yl-propyl) amide; reacting the 2-phenyl-quinolinyl-4-carbonyl chloride with a pyridylalkylamine to form the amide ASTRAZENECA AB (SE) 2008-08-21 — — US claimed
US-20070032492-A1 Cytokine Inhibitors BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2007-02-08 — — US claimed
CN-1860116-A Bicyclic compounds and compostions as pdf inhibitors IRM LLC (BM) 2006-11-08 — — CN claimed
EP-1567507-B1 1,2,3- TRIAZOLE AMIDE DERIVATIVES AS CYTOKINE INHIBITORS BOEHRINGER INGELHEIM PHARMA (US) 2006-06-14 — — EP claimed
US-20040102492-A1 Cytokine inhibitors BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2004-05-27 — — US claimed
US-12036292-B2 Heterobiaryl compounds and imaging agents for imaging huntingtin protein CHDI FOUNDATION, INC. (US) 2024-07-16 — — US disclosed
WO-2005100305-A1 ANDROGEN MODULATORS WARNER-LAMBERT COMPANY LLC (US) 2005-10-27 — — WO disclosed
US-20050239857-A1 Novel imidazoles BOLTON GARY L 2005-10-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102492-A1 Cytokine inhibitors IL1A, IL1B, IL1RN MAPT 3383/4885RAB9A 1261/4885MAPK1 315/4885
US-20080200504-A1 non-peptide NK-3 receptor ligands; anxiety, depression, schizophrenia, obesity; 2-Phenyl-quinoline-4-carboxylic acid (1-pyridin-4-yl-propyl) amide; reacting the 2-phenyl-quinolinyl-4-carbonyl chloride with a pyridylalkylamine to form the amide NPY4R, PROKR1, NPSR1 MAPT 4579/4885RAB9A 1912/4885MAPK1 1859/4885
US-20050239857-A1 Novel imidazoles HMGCR, HMGB2, HMGB3 MAPT 1367/4885RAB9A 3634/4885MAPK1 4193/4885
US-20070032492-A1 Cytokine Inhibitors IL1B, IL1A, IL1RN MAPT 2673/4885RAB9A 1170/4885MAPK1 295/4885
US-20190169180-A1 PIPERDINE CXCR7 RECEPTOR MODULATORS CXCR1, CXCR5, ACKR3 MAPT 4746/4885RAB9A 628/4885MAPK1 1111/4885
US-12036292-B2 Heterobiaryl compounds and imaging agents for imaging huntingtin protein HTT, HYPK, ATXN2L MAPT 11/4885RAB9A 535/4885MAPK1 4163/4885
US-10752620-B2 Piperdine CXCR7 receptor modulators CXCR1, CXCR5, ACKR3 MAPT 4746/4885RAB9A 628/4885MAPK1 1111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.